bioRxivCell BiologyPreprint
CRISPR/Cas9-mediated Generation of COL7A1-deficient Keratinocyte Model of Recessive Dystrophic Epidermolysis Bullosa
F. Alipour, M. Ahmadraji, E. Yektadoust, P. Mohammadi, H. Baharvand, M. Basiri
Abstract
ObjectiveRecessive dystrophic epidermolysis bullosa (RDEB) is a genetic skin fragility and ultimately lethal blistering disease caused by mutations in the COL7A1 gene which is responsible for coding type VII collagen. Investigating the pathological mechanisms and novel candidate therapies for RDEB could be fostered by new cellular models. Here, we developed multiple immortalized COL7A1-deficient keratinocyte cell lines using CRISPR/Cas9 technology as RDEB cellular model. Materials and MethodsIn this experimental study, we used transient transfection to express COL7A1-targeting gRNA and Cas9 in HEK001 immortalized keratinocyte cell line followed by enrichment with fluorescent-activated cell sorting (FACS) via GFP expressing cells (GFP+ HEK001). Homogenous single-cell clones were then isolated, genotyped, and evaluated for type VII collagen expression. We performed a scratch assay to confirm the functional effect of COL7A1 knockout. ResultsWe achieved 46.1% (p < 0.001) efficiency of indel induction in the enriched transfected cell population. Except for 4% of single nucleotide insertions, the remaining indels were deletions of different sizes. Out of nine single clones expanded, two homozygous and two heterozygous COL7A1-deficient cell lines were obtained with defined mutation sequences. No off-target effect was detected in the knockout cell lines. Immunostaining and western blot analysis showed the lack of type VII collagen (COL7A1) protein expression in these cell lines. We also showed that COL7A1-deficient cells had higher motility compared with their wild-type counterparts. ConclusionWe reported the first isogenic immortalized COL7A1-deficient keratinocyte lines that provide a useful cell culture model to investigate aspects of RDEB biology and potential therapeutic options.
- organism: human
- assay: proteomics
- research focus: cell type annotation
- approach: genetic perturbation / CRISPR
Reproducibility ledger
Nobody has reported trying to reproduce this paper yet. Did you replicate an experiment or run the code? Your report saves the next lab a week.
Sign in to file a reproducibility report.
Related papers
- Therapeutic base and prime editing of COL7A1 mutations in recessive dystrophic epidermolysis bullosa
S.-a. Hong, S.-E. Kim, … S. E. Lee·bioRxiv·Jul 12, 2021
- A scalable, GMP-compatible, autologous organotypic cell therapy for Dystrophic Epidermolysis Bullosa
G. Neumayer, J. Torkelson, … A. E. Oro·bioRxiv·Feb 28, 2023
- Contribution of HMGB1 to Keratinocyte inflammation in Recessive Dystrophic Epidermolysis Bullosa
Kacey Guenther Bui, Ya‐Chu Chang, … Hai Dang Nguyen·JID InnovationsPeer-reviewed·May 14, 2026
- Increased abundance of Cbl E3 ligases alters PDGFR signaling in recessive dystrophic epidermolysis bullosa
E. M. Martinez, R. Toelle, … J. Dengjel·bioRxiv·May 10, 2021
- CRISPR/Cas9-based disease modelling and functional correction of Interleukin 7 Receptor alpha Severe Combined Immunodeficiency in T-lymphocytes and hematopoietic stem cells
Rajeev Rai, Zohar Steinberg, … Alessia Cavazza·Human Gene TherapyPeer-reviewed·Jan 22, 2024
- Generation and Characterization of Col6a1 knock-in mice: A Promising Pre-Clinical Model for Collagen VI-Related Dystrophies
Arístides López‐Márquez, Carmen Badosa, … Cecilia Jimenez-Mallebrera·Disease Models & MechanismsPeer-reviewed·Nov 25, 2025